Publication Topic

Allen BC, Vincent MJ, Lipworth L, Panko JM, Suh M, Jiang X, Mumma MT, Proctor DM. 2025. Lung cancer risk assessment associated with exposure to hexavalent chromium: Results of pooled analysis of three cohorts. J Occup Environ Hyg 22(10):821-835; doi: 10.1080/15459624.2025.2502491.  PMID: 40435461.

Shaw J, Hsu H, Tu H, Chia V, Aggarwal S, Carrigan G, Kelsh MA. Immortal time bias impacts time-to-time event outcomes in cohort with genomic testing. Abstract 6F-03, International Society for Pharmacoepidemiology (ISPE) 41^st Annual Meeting, Washington, DC, August 2025.

Proctor D, Jiang X, Reichert H, Thompson C. 2025. Why rat oral cavity tumors should not be the basis of quantitative cancer risk assessment for oral exposure to hexavalent chromium. Toxicol Sci kfaf112; doi: 10.1093/toxsci/kfaf112. Online ahead of print August 8, 2025. PMID: 40795394.

Clouser MC, Suh M, Movva N, Hildebrand JS, Pastula ST, Schoehl M, Hindoyan A, Balasubramanian A, et al. 2025. A systematic literature review of MTAP deletions in solid and hematologic cancers. Cancer Treat Res Comm 44:100966; doi: 10.1016/j.ctarc.2025.100966. PMID: 40729867.

Price M, Suh M, Pastula S, Kruchko C, Ostrom Q. Pediatric low-grade glioma (pLGG) incidence in the United States from 2015 through 2019. Abstract LGG-04, Society for NeuroOncology (SNO) Pediatric Neuro-Oncology Conference, San Diego, CA, May 2025.

Proctor D, Thompson C. Why oral cavity tumors should not be the basis of the hexavalent chromium oral cancer slope factor-weight of evidence review. Abstract 3136, Society of Toxicology 64^th Annual Meeting, Orlando, FL, March 2025. (Honored as one of the Risk Assessment Specialty Section’s Top 10 Abstracts).

Allen B, Heitz E, Goodman S, Freedman A, Miller S, Haver C, Snow S, Weinberger K, et al. Understanding the cancer outcomes associated with exposure to jet fuels: A fit-for-purpose systematic literature review. Abstract 4676, Society of Toxicology 64^th Annual Meeting, Orlando, FL, March 2025.

Borghoff SJ, Rivera B, Fitch S, Buerger AN, Choksi N, Franzen A, Vincent MJ, Covington T, Bus J, Rushton E, Lea IA. 2025. Systematic evaluation of the evidence base on methyl tert-butyl ether supporting a lack of concern for carcinogenic hazard in human based on animal cancer studies and mechanistic data. Curr Res Toxicol 8:100224; doi: 10.1016/j.crtox.2025.100224. PMID: 40084233.

Lipworth L, Panko JM, Allen BC, Mumma MT, Jiang X, Vincent MJ, Bare JL, Antonijevic T, Vivanco SN, Marano DE, Suh M, Cohen S, Mittal L, Proctor DM. 2025. Lung cancer mortality among aircraft manufacturing workers with long-term, low-level, hexavalent chromium exposure. J Occup Environ Hyg 22(3):214-227; doi: 10.1080/15459624.2024.2439817. PMID: 39773194.

Kim A, Cong Z, Jazieh A-R, Church TR, Reichert H, Nicholson G, Fryzek J, Cohen SS. 2024. Estimating the incremental population health impact of a multi-cancer early detection (MCED) test to complement existing screening among elevated risk populations with multiple cancer risk factors: A mathematical modeling study. BMC Health Serv Res 24(1):1584; doi: 10.1186/s12913-024-12037-1. PMID: 39695574.

Bates CA, Vincent MJ, Buerger AN, Santamaria AB, Maier A, Jack M. 2024. Investigating the relationship between β-carotene intake from diet and supplements, smoking, and lung cancer risk. Food Chem Toxicol 194:115104; doi: 10.1016/j.fct.2024.115104. PMID: 39522798.

Madl AK, Donnell MT, Covell LT. 2024. Synthetic vitreous fibers (SVFs): Adverse outcome pathways (AOPs) and considerations for next generation new approach methods (NAMs). Crit Rev Toxicol 54(10:754-804; doi: 10.1080/10408444.2024.2390020. PMID: 39287182.

DiBiase JF, Scharnetzki E, Edelman E, Reed EK, Helbig P, Rueter J, Miesfeldt S, Frankenfeld CL, et al. 2024. Socioeconomic and urban-rural disparities in genome-matched treatment receipt and survival after genomic tumor testing. JNCI Cancer Spectr 8(5):pkae090; doi: 10.1093/jncics/pkae090. PMID: 39312685.

Hernandez L, Davies S, Li C, Reddick E, Jensen I. A cost-consequence analysis of ponatinib versus imatinib in patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia in the United States. Abstract EE165, ISPOR 2024 (Top 5% Finalist).

Vincent MJ, Fitch S, Bylsma L, Thompson C, Rogers S, Britt J, Wikoff D. 2024. Assessment of associations between inhaled formaldehyde and lymphohematopoietic cancer through the integration of epidemiological and toxicological evidence with biological plausibility. Toxicol Sci 199(2):172–193; doi: 10.1093/toxsci/kfae039. PMID: 38547404.

Yoshino T, Hooda N, Younan D, Muro K, Shitara K, Heinemann V,… Suh M, Reichert H, Mezzi K, Fryzek J, et al. 2024. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. Eur J Cancer 202:113975; doi: 10.1016/j.ejca.2024.113975. PMID:  38442645.

Mittal L, Perry CS, Blanchette AD, Proctor DM. 2024. Probabilistic risk assessment of residential exposure to electric arc furnace steel slag using Bayesian model of relative bioavailability and PBPK modeling of manganese. Risk Anal. 44(9):2169-2186. doi: 10.1111/risa.14309. PMID: 38622492.

Laurer D, Benson S, Marshall L, Wood L, Keeton K, Steigerwald D, Dobyns L, Finley B. Asbestos and laryngeal cancer: A fiber-type specific meta-analysis. Abstract 3392, poster presentation at Society of Toxicology 63^rd Annual Meeting, Salt Lake City, UT, 2024.

Ierardi AM, Burns A, Urban A, Finley B. 2024. A risk assessment of cosmetic talc for the development of mesothelioma and ovarian cancer. Chapter 13 in: Paustenbach DJ (ed), Human and Ecological Risk Assessment: Theory and Practice, Third Edition. Wiley, ISBN: 978-1-119-74296-8, pp. 541–570.

Vincent M, Fitch S, Bylsma L, Thompson C, Rogers S, Britt J, Wikoff D. Integration of toxicological and epidemiological information to evaluate biological plausibility and causality of associations between inhaled formaldehyde (FA) and lymphohematopoietic (LHP) cancers. Abstract 5157, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.